Dive in
We have our own point of view on the people, technologies, and conversations that will shape the future.
Predictive and generative AI are entering many new applications. At Menlo Ventures, we are especially excited about applications for AI in drug discovery and development, specifically when new technology can directly address a major unmet need.
Drug design is both a natural fit and a unique challenge for generative AI, given large but messy datasets, time and cost of real-world testing, and the complexity of human trials.
While navigating this exciting yet complex landscape may seem daunting for startups, lessons from past tech waves, along with a thoughtful, strategic approach, can help illuminate the path forward.
We stand on the precipice of an extraordinary platform shift catalyzed by groundbreaking advancements in generative artificial intelligence.
Genesis Therapeutics is pioneering AI technologies to create medicines for patients with severe and unmet medical needs.
OpenAI’s ChatGPT reached 100 million monthly active users just two months after launch, setting the new standard for the fastest-growing consumer application in history. The landmark achievement underscored the strength of generative AI’s pull in consumer markets—surpassing even the breakthroughs of the internet and smartphones.
Pinecone has raised a $100M Series B led by A16Z—with explosive growth justifying their new $750M valuation.
Since the advent of the internet, few technological advances have garnered as much attention and enthusiasm as quickly as generative AI.
